Analysis of the cytogenetic response in peripheral blood lymphocytes from breast cancer patients following chemotherapy

The presence of chromosomal aberrations induced in circulating lymphocytes from breast cancer patients during chemotherapy was analyzed. Ten breast cancer patients undergoing neoadjuvant chemotherapy and ten healthy women (controls) were evaluated. Metaphases were obtained from cultures of peripheral lymphocytes stimulated with phytohemaglutinin and metaphase blockage was achieved with colchicine. One hundred metaphases were analyzed for chromosomal aberrations and 1,000 cells for the mitotic index. No significant differences were observed regarding the frequency of chromosomal aberrations, number of cells with chromosomal aberrations and mitotic index between the controls and patients before chemotherapy. However, after the first chemotherapy cycle, the numbers of chromosomal aberrations and cells with them was greater. After the third cycle, the mitotic index was lower, but the fifth cycle produced an increase in relation to the third and fourth cycles. The results suggest that chemotherapy raises the number of chromosomal aberrations and favors persistence of stable chromosomal abnormalities.

Breast cancer; Chemotherapy; Chromosomal changes; Mitotic index.

[1] Pruthi S., Brandt K.R., Degnem A.C., Goetz M.P., Perez E.A., Reynolds C.A. et al.: “A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis”. Mayo Clin Proc., 2007, 82, 999.

[2] Chang J.C., Hilsenbeck S.G., Fuqua S.A.W.: “Genomic approaches in management and treatment of breast cancer”. Br. J. Cancer, 2005, 1.

[3] Hortobagyi G.N.: “Management of Stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy”. Cancer, 1988, 62, 2507.

[4] Moreno A., Escobedo A., Benito E., Serra J.M., Gumà A., Riu F.: “Pathologic changes related to CMF primary chemotherapy in breast cancer”. Breast Cancer Res. Treat., 2002, 75, 119.

[5] Cocquyt V.F., Cocquyt V.F., Blondeel P.N., Depypere H.T., Praet M. M., Schelfhout V.R. et al.: “Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma”. Eur J Surg Oncol., 2003, 29, 361.

[6] Silva L.M., Takahashi C.S., Carrara H.H.A.: “Study of damage in patients with breast cancer treat by two antineoplastic treatments”. Teratog. Carcinog. Mutagen, 2002, 22, 257.

[7] Chintamani S.V., Singh J.P., Lyall A., Saxena S., Bansal A.: “Is drug-induced toxicity a good predictor of response to neoadjuvant chemotherapy in patients with breast cancer? A prospective clini-cal study”. BMC Cancer, 2004, 4, 48, 1.

[8] Bernard-Marty C., Mano M., Paesmans M., Accettura C., Munoz-Bermeo R., Richard T. et al.: “Second malignancies following adju-vant chemotherapy: 6-years results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluoracyl (CMF) with an anthracycline-based regimen in adjuvant treatment of nodepositive breast cancer patients”. Ann Oncol., 2002, 14, 691.

[9] Wang X., Wu X., Liang Z., Huang Y., Fenech M., Xue J.: “A comparoson of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan”. Mutagenesis., 2006, 21, 1, 41.

[10] Campos L.M.F.R., Dias F.L., Antunes L.M.G., Murta E.F.C.: “Prevalence of micronuclei in exfoliated uterine cervical cells from patients with risk factors for cervical cancer”. São Paulo Med J., 2008, 126, 323.

[11] Baeyens A., Thierens H., Vandenbulcke K., De Ridder L., Vral A.: “The use of EBV-transformed cell lines of breast cancer patients to measure chromosomal radiosentsitivity”. Mutagenesis., 2004, 19, 4, 285.

[12] Baeyens A., Vandenbulcke K., Philippé J., Thierens H., De Ridder L., Vral A.: “The use of IL-2 cultures to measure chromosomal radiosensitivity in breast cancer patients”. Mutagenesis., 2004, 19, 6, 493.

[13] Garcia B.P., Hoegel J., Varga D., Hoehne M., Michel I., Jainta S. et al.: “Scorimg variabitiry of micronuclei in binucleated human lymphocytes in a case-control study”. Mutagenesis., 2006, 21, 3, 191.

[14] Varga D., Johannes T., Jainta S., Schuster S., Schwarz-Boeger U., Kiechle M. et al.: “An automated scoring procedure for the micronucleus test by image analysis”. Mutagenesis., 2004, 19, 5, 391.

[15] Ban S., KonomI C., Iwakawa M., Yamada S., Ohno T., Tsuji H. et al.: “Radiosensitivity of peripheral blood lymphocytes obtained from patientes with cancers of the breast, head and neck or cervix as determined with a micronucleus assay”. J. Radiat., 2004, 45, 535.

[16] Bauer V.L., Braselmann H., Henke M., Mattern D., Walch A., Unger K. et al.: “Choromosomal changes characterize head and neck cancer with poor prognosis”. J. Mol. Med., 2008, 1.

[17] Beahrs O.H.: “The American Joint Committee on Cancer”. Bull. Am. Coll. Surg., 1984, 69, 16.

[18] Moorhead P.S., Nowell P.C., Mellman W.J., Battips D.M., Hungerford D.A.: “Chromosome preparation of leukocytes cultured from human peripheral blood”. Exp. Cell Res., 1960, 20, 613.

[19] Savage J.R., Simpson P. J.: “FISH “painting” patterns resulting from complex exchanges”. Mutat. Res., 1994, 312, 51.

[20] Savage J.R.: “A note on interarm intrachange patterns resulting from dualarm fish painting”. Mutat. Res., 1997, 373, 265.

[21] Norppa H., Bonassi S., Hansteen I.L., Hagmar L., Strömberg U., Rössner P. et al.: “Chromosomal aberrations and SCEs as biomarkers of cancer risk”. Mutat. Res., 2006, 600, 37.

[22] Goodison S., Viars C., Urquidi V.: “Molecular cytogenetic analysis of a human breast metastasis model: identification of phenotype-specific chromosomal rearrangements”. Cancer Genet. Cytogenet., 2005, 156, 37.

[23] Lannin D.R., Mathews H.F., Mitchell J., Swanson M.S., Swanson F. H., Edwards M.S.: “Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast can-cer”. JAMA, 1998, 279, 1801.

[24] Packeisen J., Nakachi K., Boecker W., Brandt B., Buerger H.: “Cytogenetic differences in breast cancer samples between German and Japanese patients”. J. Clin. Pathol., 2005, 58, 1101.

[25] Berg J.B., Hutter R.V.P.: “Breast cancer”. Cancer supplement, 1995, 75, 257.

[26] Medonça M.A., Tavares-Murta B.M., Bachin E.S., Davi L.B., Murta E.F.C.: “Relationship between risk factors and tumor stage in breast cancer patients in a university hospital - Brazil”. Eur. J. Gynaecol. Oncol., 2008, 29, 80.

[27] Levine A.J.: “The cellular gatekeeper for growth and division”. Cell., 1997, 88, 323.

[28] Venkitaraman A.R.: “Cancer susceptibility and the functions of BRCA1 and BRCA2”. Cell., 2002, 108, 171.

[29] Hajra K.M., Fearon E.R.: “Cadherin and catenin alterations in human cancer”. Genes, Chromosomes Cancer, 2002, 34, 255.

[30] Rennstam K., Jönsson G., Tanner M., Bendahl P.O., Staaf J., Kapanen A.I. et al.: “Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1”. Cancer Genet. Cytogenet., 2007, 172, 95.

[31] Baria K., Warren C., Roberts S.A., West C.M., Scott D.: “Chromosomal radiosensitivity as a marker of predisposition to common cancers?”. Br. J. Cancer, 2001, 84, 892.

[32] Preston R.J., San Sebastian J.R., Mcfee A.F.: “The in vitro human lymphocyte assay for assessing the clastogenic of chemical agents”. Mutat. Res., 1987, 189, 175.

[33] Légal J.D., De Crevoisier R., Lartigau E., Morsli K., Dossou J., Chavaudra N. et al.: “Chromosomal aberration induced by chemotherapy and radiotherapy in lymphocytes from patients with breast carcinoma”. Int. J. Radiat. Oncol. Biol. Phys., 2002, 52, 5, 1186.

[34] Blasiak J., Arabski M., Krupa R., Wozniak K., Rykala J., Kolacinska A. et al.: “Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer”. Mutat. Res., 2004, 554, 139.

[35] Scott D., Barber J.B., Spreadborough A.R., Burrill W., Roberts S. A.: “Increase chromosomal radiosensitivity in breast cancer patients: a comparison of two assays”. Int. J. Radiat. Biol., 1999, 75, 1.

[36] Varga D., Hoegel J., Maier C., Jainta S., Hoehne M., Patino-Garcia B. et al.: “On the difference of micronucleus frequencies in peripheral between breast cancer patients and controls”. Mutagenesis., 2006, 21, 5, 313.

[37] Padjas A., Lesisz D., Lankoff A., Banasik A., Lisowska H., Bakalarz R. et al.: “Cytogenetic damage in lymphocytes of patients undergoing therapy for small cell lung cancer and ovarian carcinoma”. Toxicol. Appl. Pharmacol., 2005, 209, 183.

[38] M’Bemba P., Lemeux N., Chakrabartai S.K.: “Role of oxidatives stress and intracellular calcium in nickel carbonate hydroxide-induced sister-chromatid exchange, and alterations in replication index and mitotic index in cultured human peripheral blood lymphocytes”. Arch Toxicol., 2007, 81, 89.

[39] Anderson G.D.: “Sex and differences in pharmacological response: Where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics”. J. Women’s Health., 2005, 4, 19.

[40] Pagano L., Pulsoni A., Tosti M.E., Annino L., Mele A., Camera A. et al.: “Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto”. Br.J. Haematol., 1999, 106, 1037.

[41] Murta E.F., de Andrade J.M., Falcão R.P., Bighetti S.: “Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy”. Tumori, 2000, 86, 403.

[42] Mendonça M.A., Cunha F.Q., Murta E.F., Tavares-Murta B.M. “Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy”. Cancer Chemother. Pharmacol., 2006, 57, 663.